Paresthesia (Pins and Needles) News and Research

RSS

SCS therapy can be key to reducing use of opioids in patients battling chronic pain, study finds

New research has found spinal cord stimulation (SCS) therapy can be key to reducing or stabilizing the use of opioids in patients battling chronic pain.

20 Jan 2017

New high-frequency SCS technique offers better outcomes for patients with chronic back and leg pain

For patients with severe, chronic back and leg pain, a new high-frequency spinal cord stimulation (SCS) technique provides superior clinical outcomes, compared to conventional low-frequency SCS, reports a clinical trial in the November issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

31 Oct 2016

Yoga, aquatic exercise have positive influence on multiple sclerosis symptoms

Exercise can have a positive influence on certain symptoms of multiple sclerosis: Patients who do yoga and aquatic exercise suffer less from fatigue, depression and paresthesia, as reported by researchers from the University of Basel and the Psychiatric University Clinics Basel in a joint study with colleagues in Iran.

3 May 2016

Amgen’s Phase 2 data supports safety, efficacy of BLINCYTO in ALL patients with minimal residual disease

Amgen today announced that new data from three Phase 2 trials support the efficacy and safety of BLINCYTO (blinatumomab) in adults with acute lymphoblastic leukemia (ALL).

8 Dec 2015

World’s First and Only Upgradeable, Non-Rechargeable, Burst-Enabled MR-Conditional SCS System

St. Jude Medical, Inc., a global medical device company and an international leader in chronic pain therapy development, today announced the European launch of the Proclaim™ Elite Spinal Cord Stimulation System, the first and only upgradeable and non-rechargeable spinal cord stimulation (SCS) system approved to deliver burst stimulation from St. Jude Medical

2 Dec 2015

Better pain relief options for individuals with chronic back and leg pain

Chronic back and leg pain sufferers in search of better pain relief options may have a new choice. According to a study published in the Online First edition of Anesthesiology, the official medical journal of the American Society of Anesthesiologists, patients who received a novel high frequency form of spinal cord stimulation (SCS) therapy experienced significantly greater, long-term relief for both chronic back and leg pain, when compared to a traditional low frequency form of SCS therapy.

29 Jul 2015

Vitamin B12 supplements offer no benefits for neurological or cognitive function in older people

Vitamin B12 supplements offer no benefits for neurological or cognitive function in older people with moderate vitamin B12 deficiency, according to a new study published in the American Journal of Clinical Nutrition.

3 Jul 2015

Boston Scientific announces European launch of Precision Novi SCS System

Boston Scientific announces the European launch of the Precision Novi Spinal Cord Stimulator (SCS) System at the International Neuromodulation Society in Montreal, Canada. The 16-contact primary cell device has CE Mark for the treatment of chronic pain, and is the smallest high-capacity primary cell device currently available.

5 Jun 2015

First commercial procedure performed using Senza system for delivering Nevro's HF10 therapy

Nevro Corp., a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that the first commercial case has been performed in the United States under the company's May 8th, 2015 FDA approval for commercial use of the Senza spinal cord stimulation (SCS) system, which delivers Nevro's proprietary HF10 therapy.

24 May 2015

Nevro Q1 revenue increases 45% to $9.7 million

Nevro Corp., a medical device company that has developed and commercialized an innovative, evidence-based neuromodulation platform for the treatment of chronic pain, today reported financial results for the three months ended March 31, 2015.

11 May 2015

Nevro's Senza spinal cord stimulation system for delivering HF10 therapy gets FDA approval

Nevro Corp., a medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it has received approval from the United States Food and Drug Administration for its Senza spinal cord stimulation (SCS) system.

10 May 2015

Researchers developing eye tests to evaluate diabetic neuropathy receive global recognition

Researchers from QUT's Institute of Health and Biomedical Innovation developing eye tests to assess diabetic neuropathy and pave the way for earlier treatment are key partners in a consortium awarded $US1.1 million from the leading American medical research agency.

5 Dec 2014

Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

17 Nov 2014

Keele University professor receives £1.8M grant to improve primary care of sciatica patients

Professor Nadine Foster, of the Arthritis Research UK Primary Care Centre at Keele University, Staffordshire, UK, has been awarded an National Institute for Health Research Health Technology Assessment grant of £1.18 million for a randomised trial that seeks to improve the primary care management of patients with sciatica and suspected sciatica through a new approach called stratified care.

4 Jul 2014

Biogen Idec's ALPROLIX receives FDA approval for hemophilia B treatment

Today Biogen Idec announced that the U.S. Food and Drug Administration has approved ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], the first recombinant, DNA derived hemophilia B therapy with prolonged circulation in the body.

29 Mar 2014

Recombinant hormone could REPLACE calcium supplements

Results from the phase III REPLACE trial of recombinant human parathyroid hormone (rhPTH) indicate the treatment can successfully combat the underlying deficit in hypoparathyroidism.

18 Oct 2013

Lorry driver who developed PTSD after fatal collision receives £220,000

A lorry driver who developed post-traumatic stress disorder after being involved in a fatal collision has received £220,000 in an out of court settlement for his fatal accident claim.

15 Jun 2013

NACC recommendations address established pain therapies and preview potential future advances

Recommendations of the Neuromodulation Appropriateness Consensus Committee (NACC), announced at the 11th World Congress of the International Neuromodulation Society (INS), address established therapies and preview emerging and potential future advances.

13 Jun 2013

Research findings could lead to improved treatment for neuropathic pain

An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, says a key protein in Schwann cells performs a critical, perhaps overarching, role in regulating the recovery of peripheral nerves after injury.

28 Mar 2013

Genzyme announces key data from AUBAGIO Phase III trial on multiple sclerosis

Genzyme, a Sanofi company announced today that key data from the TOWER trial were presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

15 Oct 2012